Infectious Diseases and Vaccines
Leverage numerous infectious disease and vaccine experts using best-in-class data sources and the right sites.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Integrated Global Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.
COMPLIANCE OVERVIEWIntegrated Global Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
Connected Intelligence
-
AI & Machine Learning
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Genomics
WHO WE ARE
- Our Story
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
AI & Machine Learning with a healthcare IQ.
Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Unlock the power of genomic research.
IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Estimating the true disease burden of TB to effectively tackle this public health crisis
May 30, 2018
Solving public health challenges: ‘First’ step at a time
Albert Einstein once said, “If I were given one hour to save the planet, I would spend 59 minutes defining the problem and one minute resolving it”. To effectively tackle global health challenges, redefining the focus on addressing step one of a typical problem-solving model has assumed critical significance, i.e., Quantifying the extent and size of the challenge. Tuberculosis or TB, especially in LMICs, is a case in point.
TB is the leading infectious disease threat in the world, killing one person every two minutes. It is now widely recognized that a large proportion of TB patients first knock the door of a private sector provider in most LMICs; 50% or more across regions, from Sub-Saharan Africa to India to the far east - Indonesia Vietnam Philippines and Myanmar. However, the true disease burden of TB in these countries has remained elusive due to lack of aggregated and credible data from the private, especially unorganized sector and non-adherence to the notification mechanism to National TB programs.
Curious case of ‘missing’ TB patients
Globally, 40% of all TB cases are not reported to National TB programs and thus constitute the “missing patient” pool. Policy makers have long been dependent on expert opinions and extrapolations to arrive at the total number of TB cases in the private sector.
While many countries have public-sector dominated models of healthcare, countries which rely on the private sector for treatment and care of TB need to go back to the drawing board and quantify the size and extent of this burden. This will not only aid evidence-backed policy making, optimal resource allocation and targeted interventions, but allow countries to re-evaluate their health priorities.
Counting the uncounted: IQVIA model to estimate true disease burden in the private sector
In the absence of quality surveillance data, sales data of pharmaceuticals in the private sector offered a strong empirical foundation for estimating the disease burden. Leveraging on its proprietary pharma data, IQVIA devised a methodology to compute “TB patient-months” to estimate the real TB load in the private sector in India, a country which is home to the highest TB related deaths globally.
The results were astounding – For the first time, it was known that over 17 million TB patient-months existed in the Indian private sector in 2014, translating to ~2.2 Mn cases of TB, almost twice as many as estimated to be in the public sector. These findings meant huge implications for the National TB program and implored policy makers to rethink strategies to tackle the health crisis.
Resultantly, disease burden estimation using drug sales data was identified as a baseline indicator by India’s ‘National Strategic Plan for TB elimination for TB for 2017-2025’. Latest calculations for 2016 reveal there are 15 Mn patient-months in the private sector.
Source: The number of privately treated tuberculosis cases in India: an estimation from drug sales data – Arinaminpathy, Nimalan et al. The Lancet Infectious Diseases, Volume 16, Issue 11, 1255 - 1260
Leveraging the power to data to drive incremental global health gains
It is widely accepted that to bring about incremental improvements in health outcomes, an integrated approach is the need of the hour. For instance, patients with advanced HIV conditions are at a higher risk of developing opportunistic infections such as TB – Hence knowing the disease burden of HIV is as important in defeating TB as knowing the TB burden.
IQVIA’s disease burden estimation model is versatile in so far as its replication to other diseases and geographies is concerned. Diseases such as HIV/AIDS, diabetes, hypertension – treatment for which have a defined regimen and frequency and typically spread over a long period of time, are ideal use-cases for application of our model. Further, the growing challenge of anti-microbial resistance has necessitated the urgent need to quantify and analyze consumption patterns of antibiotic use. IQVIA’s model could be a handy tool here.
IQVIA has a dedicated public-health focused practice actively engaged with governments, national/international donors, non-governmental organizations (NGOs) and private sector stakeholders to support evidence-based decision making. Our service offerings include Policy and Strategic Planning, Disease Burden Assessment, Research and Analytics including undertaking large community and institutional surveys, Monitoring and Evaluations of Large programs, Procurement and Supply Chain Assessments, Digital Health in Public Health, Public-Private-Partnerships, Support Private sector engagement and Program Implementation. The public health team serves more than 20 countries in the Middle East, South Asia and African region. For more information, please reach out to Mr. Deepak Batra at DBatra@in.imshealth.com or Lokesh Sharma at Lokesh.Sharma@in.imshealth.com.
Please refer to Lancet publication for more details on IQVIA methodology on disease burden estimation in private sector: The number of privately treated tuberculosis cases in India: an estimation from drug sales data – Arinaminpathy, Nimalan et al. The Lancet Infectious Diseases, Volume 16, Issue 11, 1255 – 1260
Related solutions
Therapeutic & Specialty Expertise
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Public Health and Government
Use big data and predictive analytics to improve human health.
Industry Segments
See how we partner with organizations across the healthcare ecosystem, from emerging biotechnology and large pharmaceutical, to medical technology, consumer health, and more, to drive human health forward.